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Despite the discovery of the tubercle bacillus more than a hundred years ago, and allthe advances in our knowledge of the disease since then, tuberculosis still remains
one of the major health problems facing mankind, particularly in developing countries.
About one third of the World’s population is infected with M. tuberculosis. It is estimated
that currently there are about 9 million new cases of tuberculosis with 3 million deaths
worldwide. More people die of tuberculosis than any other infectious disease. Death
from tuberculosis comprises 25% of all avoidable deaths in developing countries. Ninety
five per cent of tuberculosis cases and 98% of tuberculosis deaths are in developing
countries and 75% of tuberculosis cases are in the economically productive age group1.
Geographically, the regions with the highest prevalence and infection rates are the eastern
fringe of Asia, the Indian subcontinent, the South eastern part of Africa, South-east Europe,
Central America and the Western part of the South America. The WHO has declared a
global emergency in 1993 with respect to reemerging menace of tuberculosis2.
Epidemiology of tuberculosis in India
In India, out of a total population of approximately 950 million people, each year
over 200 million develop active disease and upto 500,000 people die which roughly accounts
for one sixth of the 3 million deaths occurring due to tuberculosis globally. It implies that
every minute, a death occurs due to tuberculosis in our country2. It also imposes a cost on
economy in terms of current and future output loss because of premature death and ill
health3.
HIV and tuberculosis
HIV has a serious effect on tuberculosis in many parts of the world. Tuberculosis
is considered as one of the most common human immunodeficiency virus (HIV) related
opportunistic infections. The frequency with which HIV and M. tuberculosis infection
occur together is determined by the epidemiology of each disease in a given population.
The epidemic of HIV associated tuberculosis has been well documented in many places
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including sub-Saharan Africa and United States of America. WHO’s global tuberculosis
programme has estimated that the total number of new tuberculosis cases attributable to
HIV will rise from 3 lakh in 1990 to around 1.4 million by the year 2000. The percentage
of tuberculosis cases due to HIV infection will thus rise from 4% to 14% of the total
number of cases. The annual risk of breaking down with tuberculous disease among dually
infected persons is around 10% per year compared to 10% life time risk among those
infected with tuberculosis alone. Approximately 6 million people are currently co-infected
with tuberculosis and HIV worldwide4. Although accurate estimates are not available for
India, available reports indicate that the prevalence of HIV in tuberculosis patients is
increasing all over the country from 2% to 24%. With the spread of HIV epidemic, several
countries have observed a rapid increase in the incidence of tuberculosis. The mortality
and morbidity caused by the combined onslaught of the dual infection is quite alarming5.
The level of initial drug resistance is said to be an epidemiological indicator to assess the
amount of resistant bacterial transmission in the community. The prevalence of drug
resistant tuberculosis varies considerably throughout the world. The reasons for this are
selection of patients studied, misuse of drugs and the quality of enquiry regarding previous
treatment etc. A decline in the percentage of drug resistance in tuberculosis was observed
in Korea and New York city in recent years. But in India, the percentages have remained
static or increased and over the years the initial resistance to isoniazid as single agent is
shown to range from 0.6-13.2%, streptomycin from 2.2-7.0% and rifampicin from 0-
1 7%6. .
The prevalence of MDR TB in India is low in most of the regions and ranges from
0-6%. Primary MDR TB is found to be <3.2% and the level of acquired MDR-TB is
<6.0% except in Gujarat (14-18.5%) and North Arcot, Tamil Nadu (20.3%) and in new
Delhi (13.3%) where a high level was reported. When compared to the prevalence of
MDR-TB in other parts of the world where upto 48% have been encountered, lower levels
of resistance are evident from Indian studies.
Laboratory diagnosis
For an infectious disease like tuberculosis, which is transmitted by aerosol
droplets, the rapid and accurate detection of M. tuberculosis is essential not only to speed
up the treatment of the patient but also to control the spread of the disease in the population.
Traditional approach
1. Microscopy
Microscopy is the simplest and most rapid procedure currently available to detect
acid-fast bacilli (AFB) in clinical specimens by Ziehl Neelsen or Kinyoun staining
procedure. The limit of detection with this method is 5000-10,000 bacteria per ml of
sputum. Introduction of fluorochrome dyes such as Auramine O in place of the traditional
basic fuchsin dyes made smear reading advantageous as the yellow-fluorescing bacilli are
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easier to detect than the red fuchsin-stained organisms seen in Ziehl-Neelsen or Kinyoun
staining. Further, in the fluorescent microscopy, smears are read in low power where larger
areas are screened in less time.
The results of smear microscopy can be influenced by many factors such as the
type of specimen, the mycobacterial species, decontamination methods used, the thickness
of the smear, the extent of decolorization, the type of counter stain used, and the training
and experience of the person evaluating the smear. A new approach to increase the smear
sensitivity is to use cytocentrifuges7. The main advantage of sputum smear microscopy is
that it is inexpensive, well-established, extremely reliable and results can be reported within
hours of receipt of the sample. However, viability of the organism and species identification
are not possible with this technique.
II. Culture and drug susceptibility
Isolation of mycobacteria from clinical specimens has solely depended on the
use of media such as the egg-based Lowenstein-Jensen (LJ) medium, Middlebrook 7H11
agar, Middlebrook 7H9 broth and Kirchner’s liquid medium. The major constraint of this
procedure is the slow growth of mycobacteria which necessitates a mean incubation period
of 4 weeks on these conventional media. The drug susceptibility tests to the antituberculosis
drugs require additional 4 weeks before results can be obtained.
Modern approaches
Today, there are a few rapid methods for the culture of mycobacteria. These
include microcolony detection on solid media, the Septi-Chek AFB method, mycobacterial
growth indicator tube (MGIT) system, radiometric Bactec 460 TB method and Bactec
MGIT 960 method.
I. Microcolony counting method
In this method, plates poured with thin layer of Middlebrook 7H11 agar medium
are incubated and examined microscopically on alternate days for the first 2 weeks and
less frequently thereafter. For microscopic examination, the plates are inverted on the
stage of a conventional microscope and the objective is focussed on the surface of the
agar. In less than 7 days, microcolonies of slow growing mycobacteria such as M.
tuberculosis can be detected using this method. Though this method is less expensive and
requires about half the time needed for conventional culture, the recovery of mycobacteria
is less efficient and it is labour intensive8.
II. Septi-Chek AFB system
It consists of a liquid phase 7H9 broth with three solid media the middle brook
7H11 agar, modified egg medium and chocolate agar. This biphasic medium is presented
in a self contained CO2 environment. This non-radiometric approach has the potential to
expedite processing, obviate CO2 incubation requirements and facilitates early detection
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of positive cultures. This method requires about three weeks of incubation. The unique
advantage of this technique is the simultaneous detection of M. tuberculosis, non
tuberculous Mycobacteria (NTM), other respiratory pathogens and even contaminants. It
has been reported from multi-centric studies conducted by different groups that this system
gives a better culture result when compared to other methods including BACTEC9.
III. Mycobacterial growth indicator tube (MGIT) system
It is a non radiometric broth method for the growth and detection of mycobacteria
from clinical specimens. The MGIT system consists of a Middlebrook 7H9 broth and a
fluorescent compound embedded in silicone. Antibacterial antifungal agents and growth
supplements are added before inoculation. Positive cultures are detected visually because
of the metabolic depletion of oxygen, which otherwise quenches fluorescence.
Instrumentation is not required, and multiple tubes can be inspected simultaneously. The
tube is examined under UV light where the growth is indicated by an unmistakable orange
fluorescent glow. In several studies conducted elsewhere, it was found that the culture
sensitivity of this method in both smear positive and smear negative samples compared
well with the BACTEC 460 and it was better than the conventional egg based method10.
IV. Radiometric BACTEC 460 TB method
This technique is specific for mycobacterial growth, wherein C14 labelled palmitic
acid in 7H12 medium is used. This system detects the presence of mycobacteria based on
their metabolism rather than their visible growth. When the 14C-labelled substrate present
in the medium is metabolized, 14CO2 is produced and measured by the BACTEC 460
instrument and reported in terms of growth index (GI) value. In addition to detecting
mycobacteria, BACTEC system is also useful in the identification of M. tuberculosis
using the specific inhibitor p-nitro-alpha-acetylamino-beta-hydroxypropiophenone (NAP).
The NAP differential procedure has been shown to be a rapid and reliable method for
identifying M. tuberculosis. Using the same system, drug susceptibility tests can be
performed for all the antituberculosis drugs when sufficient growth index (GI) is observed.
Mycobacteria in clinical samples can be detected in half the time that is needed for
conventional culture methods.
A comparison of the BACTEC radiometric method with the conventional culture
and drug susceptibility testing methods on isolates from clinical specimens was undertaken
at our Centre. The results showed that the rate of isolation of positive culture was
significantly faster with the BACTEC method, with 87% of the positives being obtained by
7 days, and 96% by 14 days. There was a good correction in drug susceptibility tests and
most of these results became available within 8 days by the BACTEC method. By facilitating
early diagnosis, the BACTEC method may prove to be cost effective in a population with a
high prevalence of tuberculosis9,11.
V. BACTEC(R) MGIT 960 Mycobacteria detection system
It is an automated system for the growth and detection of mycobacteria with a
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capacity to incubate and continuously monitor 960 MGIT culture tubes. The culture tube
contains same Middlebrook 7H9 broth base, OADC enrichment and PANTA antibiotic
mixture as does the manual MGIT, except the final volume here being 7 ml. After adding
0.5 ml inoculum of the processed specimen, the tubes are incubated at 37°C in the BACTEC
MGIT 960 instrument, and are monitored automatically every 60 minutes for increase in
fluorescence. Growth detection is based on the AFB metabolic O2 utilization and subsequent
intensification of an O2 quenched fluorescent dye contained in a tube of modified MGIT.
A series of algorithms are used to determine presumptive positivity and alert the operator
to the presence and location of positive tubes.
In a multi-centre evaluation of the BACTEC MGIT 960 system, three high-volume
testing sites in USA compared the growth and recovery of AFB to that of the BACTEC 460
TB and conventional culture. Comparison of average time of detection between paired
specimens showed that, the BACTEC 460 TB and BACTEC MGIT 960 systems were 8.7
versus 8.6 for MAC and 13.4 versus 15.5 days for M. tuberculosis respectively. According
to these investigators the BACTEC MGIT 960 system exhibits greater potential as a rapid,
accurate and cost effective method for a high volume AFB laboratory12.
Species identification
The conventional procedures include tests such as determination of growth rate,
growth at different temperatures, colony morphology, pigment production and susceptibility
to para-nitrobenzoic acid (PNB). The main disadvantage here is that species identification
takes an additional 4 weeks using these methods.
I. High performance liquid chromatography (HPLC)
In this technique, the pattern of long chain high molecular weight fatty acids unique
to mycobacteria and related genera, namely the mycolic acids, is generated and compared
using an automated chromatograph after extraction of the lipid component of the
mycobacterial cells using standardized protocols. These patterns have been found to be
species-specific thus allowing rapid identification of mycobacterial cultures. Software
based on mycolic acid patterns for correct identification of the most commonly
encountered mycobacterial species in the clinical laboratory is now commercially available.
This method is reliable, easy to perform and less expensive than DNA based identification
methods such as DNA probes and PCR. However, this technique requires considerable
expertise13.
II. DNA probes
The nucleic acid base-pairing is intrinsically very specific and nucleic acid probes
have been developed which are capable of recognizing specific portions of DNA or RNA.
The choice of the target DNA sequence for a DNA probe determines the specificity and
sensitivity of the test. The probe can consist of a fragment of the mycobacterial genome,
a cloned DNA fragment or a synthetic oligonucleotide. The nature of the probe influences
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its specificity. The sensitivity of the probe depends on the detection system and the copy
number of the target sequence in the genome. Usually better results are obtained if the
probe is targeted to sequences present in multiple copies in the target cell (in this case the
mycobacterium) or if the target sequence is present in the form of repetitive DNA or
ribosomal RNA. Commercially available DNA probes hybridize to species-specific rRNA
sequences of M. tuberculosis, M. avium, M. intracellulare, M. kansasii or M. gordonae.
The mycobacterial probes developed by Gen-Probe (San Diego, CA) were originally
labelled with 125I and required physiological separation of hybridized and unhybridised
probe before detection in the gamma counter. Now the commercial probes use a
chemiluminescent (nonradioactive) label and the hybridized and unhybridised probe are
separated by adding a chemical ‘selection’ agent. The chemiluminescent procedure requires
a nominal time of 45 minutes and the acridinium ester label is more stable and extends the
shelf life of the probe reagent to about 6 months. However, these probes still require
about 1-3x107 bacilli for a positive test result while traditional culture techniques require
about 102 bacilli/ml or sputum. This indicates that RNA as a target may not provide the
required sensitivity of direct detection of mycobacteria in clinical samples. Another method
using solid phase (nylon membrane) non radioactive DNA hybridization has been developed
for identifying M. tuberculosis and M. avium intracellulare by Sygene Inc. (San Diego,
CA). This method uses oligonucleotide probes with an alkaline phosphatase label and
hybridization of the probe to the target is detected with a chromogenic substrate (reduction
of nitroblue tetrazolium)14.
III. Nucleic acid amplification
Nucleic acid (DNA or RNA) amplification techniques can detect and identify
mycobacteria directly in clinical samples. The most commonly used method is the
polymerase chain reaction (PCR). In this technique, target DNA sequences are
exponentially amplify in repeated cycles of DNA synthesis driven by specific
oligonucleotide primers. The amplified DNA is usually detected by agarose gel
electrophoresis. Today, many PCR assays are available for the detection of M. tuberculosis
complex in clinical samples. The most common of these is the one using the insertion
sequence IS6110 which is present only in mycobacteria belonging to the M. tuberculosis
complex. Like microscopy, PCR results can be obtained within 24 hours of receipt of the
sample. It is, however, important to remember that sensitivity and rate of correct
identification varies widely between different laboratories. There is, therefore, a need to
develop an effective system to carefully monitor the sensitivity since clinical samples
may contain DNA polymerase inhibitors. To control such inhibition, it is now common
practice to add a small amount of M. tuberculosis DNA to the sample. However, this step
considerably increases the number of PCR assays necessary for each clinical sample. The
latest development in this regard is the construction of a modified M. smegmatis strain
with a modified IS6110 fragment integrated into the genome which can serve as an efficient
internal control to monitor the efficacy of DNA extraction and to detect the presence of
PCR inhibitors. It is also absolutely necessary to evolve a system to prevent contamination
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with DNA fragments. The most frequent cause of false-positive results is contamination
with minute amounts of amplified DNA fragments (amplicons) via aerosols spread by
laboratory workers during handling of the PCR products. Contamination with one molecule
is sufficient for a false-positive PCR result. The use of uracil DNA glycosylase in
combination with dUTP instead of dUTP can efficiently prevent amplicon contamination.
Photochemical inactivation also prevents aplicon contamination. At the present time, it
can be said for all PCR-based approaches for species identification that strict quality control
of PCR reaction mixtures and monitoring of the performance of the amplification itself is
essential if PCR is used for diagnostic purposes. Recently a commercial PCR amplification
kit for detection and identification of M. tuberculosis has been developed (Amplicor,
Hoffman-LA Roche, Basel, Switzerland). The target for the PCR is the 16s rRNA sequence.
The detection system requires hybridization with a M. tuberculosis complex-specific
capture probe in a microplate format.
The current commercially available amplification tests are expensive and do not
have any control for inhibitors of amplification. This may produce false-negative reactions.
The main advantage of this technique over conventional microscopy and culture is the
speed with which the diagnosis can be made and direct identification of the infecting
mycobacterium.
A recent modification of nucleic acid amplification is the strand displacement
amplification (SDA) method which is an isothermal, in vitro amplification of nucleic acids.
The system has been designed to amplify either the 16S rRNA gene sequence of
mycobacteria or the insertion element IS6110 for M. tuberculosis. The main advantage of
this method is that it works at a single temperature which eliminates the need for expensive
thermal cyclers required by the PCR method. Additionally, it is not susceptible to
contaminating ribonuclease activity which are a major problem in clinical samples,
However, isothermal techniques require additional restriction enzymes which may increase
the overall cost of the procedure. It should also be borne in mind that this procedure is
still being evaluated15,16.
Molecular basis of drug resistance
Since multi-drug resistant tuberculosis strains (i.e. resistance to at least rifampicin
and isoniazid) are rapidly emerging and further burdening the already considerable global
tuberculosis problem, it is becoming imperative to rapidly diagnose drug resistant M.
tuberculosis strains17.
In contrast to other bacteria, drug resistance in M. tuberculosis is not plasmid
mediated. Although molecular events that are responsible for drug resistance have not
been well defined in all cases, recent studies have shown a tremendous progress. INH
resistant mutants of M. tuberculosis strains frequently showed catalase negative phenotype
which could be attributed to deletion or some point mutation in Kat G gene18,19. Recently,
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resistance to rifampicin was found to be determined by mutations causing change in the
rpo B gene coding for Beta-subunit of RNA polymerase21 Streptomycin-resistant mutants.
show alterations in the ribosomal protein S12 and/or in the highly conserved rspl gene,
which encodes the S12 ribosomal protein. The single amidase enzyme with both
pyrazinamidase (PZase) and nicotinamidase activities in M. tuberculosis is the target for
pyrazinamide. The mutations in pnc A gene encoding the amidase enzyme confers resistance
to pyrazinamide in M. tuberculosis complex22. Quinolones and coumarins are the known
inhibitors of the DNA gyrase. The gyrA mutations have been found to be associated with
resistance to quinolones23.
Techniques such as single strand cellular polymorphism (SSCP) could identify
mutations is short pieces of DNA. DNA of interest could be amplified by the polymerase
chain reaction (PCR). The PCR-SSCP technique has been successfully explored for the
detection of mutations in the rifampicin resistance and also resistance for streptomycin
and quinolones24.
A new technique called the Line Probe Assay (LiPA) also has been evolved using
PCR to amplify the region of RNA polymerase involved in rifampicin resistance. A set of
oligonucleotide probes are immobilized onto a membrane strip and rifampicin resistance
can be assessed from the pattern obtained following hybridization. This technique is
undergoing rigorous analysis at the moment25.
Phage reporter assay
In this technique, viable mycobacteria are infected with specific reporter phages
expressing firefly luciferase gene. Easily detectable signals are apparent a few minutes
after infection of M. tuberculosis with reporter phages. Light production requires
metabolically active M. tuberculosis cells, in which reporter phages replicate and luciferase
gene is expressed. When drug-susceptible M. tuberculosis strains are incubated with
specific anti-tuberculosis drugs, they fail to produce light after infection with luciferase
reporter phages. In contrast, drug-resistant strains are unaffected by the drugs and produce
light at levels equivalent to those documented for untreated controls after infection with
reporter phages. This procedure may reduce the time required for susceptibility testing of
M. tuberculosis strains. The applicability of this technique to drug susceptibility testing
of non-tuberculous mycobacteria is yet to be explored 26,27. An evaluation of a new rapid
bacteriophage-based method for the drug susceptibility testing of M. tuberculosis has
been reported recently by Wilson S M et al by the Pha B assay. The concept of this assay
is based on the ability of viable M. tuberculosis bacilli to protect infecting
mycobacteriophage from inactivation by phagocidal chemicals. It follows that after
incubation with drugs only those M. tuberculosis that remain viable (i.e. are drug resistant)
can protect the mycobacteriophage. Any mycobacteriophage protected within viable bacilli
replicate and ultimately lyse their host. For rapid detection, the released mycobacteriophage
are mixed with a rapidly growing M. smegmatis host in which they undergo rapid cycle of
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infection, replication and lysis. Lysis is easily seen as clear areas or plaques in a lawn of
rapid grower host. The number of plaques generated from a given sample is directly related
to the number of protected mycobacteriophage, which is dependent on the number of M.
tuberculosis bacilli that remain viable after drug treatment.
Antibody detection
In this technique, antibodies against mycobacterial antigens in sera from patients
by enzyme-linked immunosorbent assay (ELISA) is done using polyclonal or monoclonal
antibodies. When crude mycobacterial preparation are used for these tests, the test has
low specificity. False-positive results are likely to be due to cross-reactions by
environmental mycobacteria and other bacteria. To prepare purified antigens from
mycobacterial cultures, techniques such as ion-exchange chromatography, gel filtration,
isoelectric focusing, electrophoresis and affinity chromatography are required. Purified
antigens improve the specificity of the antibody detection assays. However, reproducible
methods for the purification of mycobacterial antigens have yet to be evolved which means
that the results of such assays are variable. The most promising purified antigen among
those available so far are the 38kDa and Ag60 antigens from M. tuberculosis 28.
At this point it is worthwhile to mention that the immune response is mycobacterial
disease appears to be associated with HLA class type II allotypes and different patients
appear to recognize different antigens29 . This suggests that it is unlikely that all tuberculosis
patients will recognize a single antigen. This may prove to be a handicap as far as antibody-
based detection systems for mycobacteria are concerned30.
DNA strain typing using restricted fragment length polymorphism (RFLP)
The principle behind the RFLP technique is that if a single base difference between
otherwise two identical pieces of double stranded DNA is lying within the recognition site
of restriction endonuclease, then digestion of both the samples with that restriction
endonuclease will produce different products which can be resolved by electrophoresis
resulting in different handling patterns called as Genomic or DNA fingerprints. Differences
in banding patterns are referred to as RFLPs. RFLP typing of M. tuberculosis isolates is
useful for epidemiological investigations in the spread of particular strains, especially
multi-drug resistant strains and also to learn about relapses following successful treatment
whether it is due to endogenous reactivation or exogenous infection31,32.
Conclusions
The epidemiological situation of tuberculosis in India is complex with a very
wide variation in the annual risk of infection, prevalence of disease and the pattern of
antituberculosis drug resistance. Besides, the concentration of the disease among young
age group makes tuberculosis as a major socio-economic problem. The burden is likely
to increase with the onslaught of HIV epidemic with an increase of cases having dual
infection, increase in morbidity and mortality due to tuberculosis. Improvement in case
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detection will require development of rapid diagnostic tools with the aim to increase
sensitivity, specificity and technical simplicity. This is vital in cutting the chain of
transmission among the vulnerable population.
Today, many new techniques are available for the diagnosis of tuberculosis and
also for detection and identification of M. tuberculosis. However, detection of AFB by
direct microscopy and identification of cultured mycobacteria by biochemical methods
still remain the recommended methods. Faster culture methods using radiometric systems
such as Bactec etc. are being increasingly used mainly because they reduce the time of
culture to about 2 weeks. Nucleic acid amplification techniques are mainly for cases
where there is a chance that the infection may be due to a mycobacterium other than M.
tuberculosis. It is also to be remembered that most of the new techniques described
involve prohibitive expenditure in terms of instrumentation, expertise and reagents, putting
them out of the reach of many public health laboratories of developing countries, especially
India.
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